In conclusion, our in vitro results indicate that spliceosome inhibitors would be promising molecular target therapy in SCLC irrespective of the MYC status, especially in the second-line settings after an effective front-line chemotherapy. The gene discussed is MYC; the disease is small cell lung carcinoma.